

**REED, JARRED PRINCE, M.D.**

**CURRICULUM VITAE**

**EDUCATION:**

2005-2009 Georgetown University  
Washington, D.C.  
Degree: B.S. Biochemistry

2009-2013 Duke University School of Medicine  
Durham, NC  
Degree: M.D.

2014 UCLA Ronald Reagan Medical Center  
Los Angeles, CA  
Internship, Internal Medicine

2014-2016 UCLA Ronald Reagan Medical Center  
Los Angeles, CA  
Residency, Internal Medicine

2017-2020 Olive View-UCLA Medical Center  
Sylmar, CA  
Fellowship, Hematology-Oncology

**LICENSURE:**

California Medical License #A134037  
Drug Enforcement Agency Number FR5759040

**BOARD CERTIFICATION:**

2016-2023 Internal Medicine, ABIM  
2020-present Medical Oncology, ABIM  
2020-present Hematology, ABIM

## **ACADEMIC APPOINTMENTS:**

7/2016-6/2017 Health Sciences Clinical Instructor  
David Geffen School of Medicine at UCLA  
Los Angeles, CA

7/2020-6/2021 Health Sciences Clinical Instructor  
David Geffen School of Medicine at UCLA  
Olive View-UCLA Medical Center  
Sylmar, CA

7/2021-present Health Sciences Assistant Professor  
David Geffen School of Medicine at UCLA  
Olive View-UCLA Medical Center  
Sylmar, CA

## **PROFESSIONAL EXPERIENCE:**

7/2016-6/2017 Attending Physician  
Ronald Reagan UCLA Medical Center  
Department of Medicine  
Los Angeles, CA

7/2020-present Physician Specialist  
Olive View-UCLA Medical Center  
Division of Hematology/Oncology  
Sylmar, CA

7/2023-present Associate Program Director, Hematology/Oncology  
Fellowship Program  
Olive View-UCLA Medical Center  
Division of Hematology/Oncology  
Sylmar, CA

## **PROFESSIONAL ACTIVITIES:**

2017-present American Society of Clinical Oncology, member

2017-present American Society of Hematology, member

2020-present Econsult reviewer, responsible for reviewing  
Hematology/Oncology consults from assigned community  
clinics, Olive View-UCLA Medical Center

## **Committees:**

|              |                                                                                                                  |
|--------------|------------------------------------------------------------------------------------------------------------------|
| 2020-present | Member, Hematology/Oncology Fellowship Competency Committee – Olive View-UCLA Medical Center                     |
| 2021-present | Member, IRB Committee, Olive View-UCLA Medical Center                                                            |
| 2022-present | Member, DHS Genetics and Genomics Working Group                                                                  |
| 2022-present | Hematology/Oncology Lead, GI Lead, Local Champion, Olive View-UCLA Medical Center Cancer Care Navigation Program |

#### **HONORS AND SPECIAL AWARDS:**

|      |                                                                                      |
|------|--------------------------------------------------------------------------------------|
| 2014 | Commendation for Excellence in Medical Student Teaching, UCLA Department of Medicine |
| 2015 | Commendation for Excellence in Medical Student Teaching, UCLA Department of Medicine |
| 2017 | Nominee, consultant of the semester, UCLA Department of Emergency Medicine           |
| 2021 | Physicians for a Healthy California CalHealthCares Awardee                           |

#### **RESEARCH GRANTS AND FELLOWSHIPS RECEIVED:**

|           |                                                                                                                                                                                                                                                                   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2011-2012 | Howard Hughes Medical Institute Medical Research Fellow, Duke University School of Medicine                                                                                                                                                                       |
| 2019      | ASCO/AACR Methods in Clinical Cancer Research Workshop, Fellow, for proposed protocol “A phase 2 study of CB-839, antagonizing glutaminase, in combination with enzalutamide or abiraterone in prostate cancer patients progressing on androgen targeted therapy” |

#### **LECTURES AND PRESENTATIONS:**

|        |                                                                                                                                                                                            |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 9/2011 | Reed JP, Kincaid B, Muzyk A, Preud' Homme X. Thiamine deficiency: consequence or cause?. Poster presented at: Association of Medicine and Psychiatry 2011 Annual CME Meeting; Chicago, IL. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|         |                                                                                                                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5/2012  | Reed JP, Wu J, Brian L, Freedman N. (2012, May). G protein-coupled receptor kinase-5 attenuates signaling through the colony-stimulating factor-1 receptor. Poster presented at: Howard Hughes Medical Institute Medical Research Fellows May Meeting; Bethesda, MD. |
| 10/2019 | Reed JP, Gong J, Figlin RF. Brain Metastases in Renal Cell Carcinoma: Case Report of Brain Complete Response to Cabozantinib and Review of Current Evidence. Poster presented at: Annual Global Summit on Genitourinary Malignancies 2019; Bannf, Canada.            |
| 2021    | House Staff conference presented/lecturer. "Plasma Cell Disorders" August 2021.                                                                                                                                                                                      |
| 2021    | House Staff conference presented/lecturer. "Colorectal Cancer" August 2021.                                                                                                                                                                                          |
| 2022    | House Staff conference presented/lecturer. "Plasma Cell Disorders" August 2022.                                                                                                                                                                                      |
| 2022    | House Staff conference presented/lecturer. "Colorectal Cancer" August 2022.                                                                                                                                                                                          |
| 2023    | Hematology/Oncology Fellow Orientation Lecture Series. "Hematologic Emergencies." July 2023.                                                                                                                                                                         |
| 2023    | Hematology/Oncology Fellow Orientation Lecture Series. "Bone Marrow Consents, Indications, Simulation." July 2023.                                                                                                                                                   |
| 2023    | Hematology/Oncology Fellow Orientation Lecture Series. "Genitourinary Malignancies." July 2023.                                                                                                                                                                      |

#### ACADEMIC ACTIVITIES:

|              |                                                                                           |
|--------------|-------------------------------------------------------------------------------------------|
| 2020-present | Moderator, Hematology/Oncology Journal Club with fellows-monthly                          |
| 2020-present | Moderator, Hematology/Oncology Leukemia/Lymphoma Conference (residents, fellows)- monthly |
| 2020-present | Moderator, Hematology/Oncology Core Curriculum Lecture Series- bimonthly                  |

|              |                                                                                                                                                      |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2020-present | Moderator, Hematology/Oncology Tumor Board (residents, fellows)- weekly                                                                              |
| 2020-present | Participant, Hematology/Oncology Hepatobiliary Tumor Board (residents, fellows)- monthly                                                             |
| 2020-present | Participant, Thoracic Oncology Tumor Board (residents, fellows)- monthly                                                                             |
| 2020-present | Attending, Inpatient Hematology/Oncology Consult Service. Supervising and teaching medical students, residents and fellows. (2-3 months/ year)       |
| 2020-present | Attending, Inpatient Hematology/Oncology Ward Service. Supervising and teaching medical students, residents and fellows. (2-3 months/ year)          |
| 2020-present | Attending, Special Treatment Infusion Center. Supervising and teaching residents and fellows (2-3 months/year)                                       |
| 2020-present | Attending, Hematology/Oncology Outpatient Clinics. Supervising and teaching medical students, residents and fellows (3-4 half days/week)             |
| 2020-present | Faculty Supervisor for fellow/division Performance Improvement projects (3 fellows/year)                                                             |
| 2020-present | Hematology/Oncology fellow lecture series – Quarterly                                                                                                |
| 2020-present | Internal Medicine Resident noon conference lecture series – Bi-annually                                                                              |
| 2020-present | Faculty Supervisor for Hematology/Oncology Fellow Research projects (3-4 fellows/year)                                                               |
| 2020-present | Co-instructor, Internal Medicine 4 <sup>th</sup> year Hematology/Oncology Sub-Internship rotation (ME240.05): 1 student/block, UCLA David Geffen SOM |

#### **ACTIVE PROJECTS:**

|                |                                                    |
|----------------|----------------------------------------------------|
| 2021 – Present | Gynecology-Oncology Clinical Trial Co-Investigator |
|----------------|----------------------------------------------------|

GOG #3024 PI: Christine Holschneider, MD A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer OVMC IRB # 1318616 Activated: 2/26/2019 IRB expiration Date: 4/25/2023 Consent in ENGLISH & SPANISH ONLY Protocol Version: 10.0 11/19/2021

GOG#3038/INCMGA00012-204 PI: Mae Zakhour, MD An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) OVMC IRB#: 1747196 Activated: 05/25/2021 IRB Expiration: 05/23/2023 Consent in ENGLISH & SPANISH ONLY Protocol: Version 3 dtd 12Jul2021

GOG #3059 PI: Mae Zakhour, MD Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC) OVMC IRB#: 1784064-4 Activated: 28Sep2021 IRB Expiration: 27Sep2022 Consent currently in ENGLISH ONLY Protocol Version: 4.0 dtd 24May2022Olive View-UCLA Medical Center

2021- present

TRIO Network Trials Co-Investigator

TRIAL TRIO-US-L06 – CLOSED TO ENROLLMENT Lung CA An Open-Label Phase Ib/II Trial of Niraparib and Temozolomide with Atezolizumab vs. Atezolizumab alone as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (TRIO-US L-06)

TRIAL AZ Matterhorn -OPEN FOR ENROLLMENT Gastric or GEJ CA. A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant

Durvalumab in Patients with Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

TRIAL AMEERA/Sanofi – CLOSED TO ACCRUAL Breast CA. A randomized, multicenter, double-blind Phase 3 study of amcenestrant (SAR439859) plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

TRIAL Lilly JPCW Breast CA eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-

Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

TRIAL Infinity IPI-549-03 – OPEN FOR ENROLLMENT Breast CA A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma

TRIAL Ambrx ACE-Breast -03 -OPEN FOR ENROLLMENT Breast CA. A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens

TRIAL Mirati SRQ USA Only - OPEN TO ENROLLMENT Colorectal CA849-010: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

TRIAL NOVARTIS HER2+ CBYL719G12301 EPIK B-2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of apelsib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation Breast CA

TRIAL Novartis C2202/ HER- Breast CA. CBYL719C2202:EPIK-B4: A Phase II, multicenter, Randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy.

TRIAL Amgen 20210096 Gastric or GEJ. A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)

TRIAL Lilly JPEF Breast CA. 13Y-MC-JPEF. postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast

**REED, JARRED PRINCE**

**BIBLIOGRAPHY**

**RESEARCH PAPERS (PEER REVIEWED)**

1. Pennington JD, Eilber FC, Eilber FR, Singh AS, **Reed, JP**, ... Kamrava M. (2018). Long-term Outcomes with Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas. American Journal of Clinical Oncology, 41(12), 1154–1161. \*Performed retrospective chart review and collected data in spreadsheet format for analysis by other study authors.
2. **Reed JP**, Chung J, Banerjee N. A Case of Cobalamin Deficiency and Macrocytic Anemia Secondary to Sunitinib. Cureus. <https://doi.org/10.7759/cureus/4310>. 2019.
3. Nachtigal E, **Reed J**. (2023). Miracle on Irinotecan. Proceedings of UCLA Healthcare Volume 27.

**RESEARCH PAPERS - NON-PEER REVIEWED**

1. **Reed JP**, Garg D, Lin PF. (2014). A Case of Anterior Cervical Osteophytes. Proceedings of UCLA Healthcare. Volume 18.

**REVIEWS**

1. **Reed JP**, Posadas EM, Figlin RA. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma. Expert Rev Anticancer Ther. 2019;19(3):259-271.
2. Adashek JJ, **Reed JP**, Tandon A, et al. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. Clin Genitourin Cancer. 2020; Dec; 18(6):425-428

**EDITORIALS**

1. **Reed JP**, Posadas EM, Figlin RA. Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous. J Clin Oncol. 2019;37(23):1987-1989.
2. **Reed JP**, Devkota S, Figlin RA. Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer. Ann Transl Med. 2019;7(Suppl 8):S309.

**POSTERS**

1. Zarrinkhoo E, Wilkinson J, Bolos D, **Reed J**. Extra-Corporeal Membrane Oxygenation as a Bridge to Recovery in Choriocarcinoma Syndrome. California Thoracic Society. March 11 2022. Los Angeles, CA, United States.
2. Jeong I, Bhardwaj S, Lo A, **Reed J**. A Rare Case of Coexisting Polycythemia Vera and Chronic Myelogenous Leukemia. UCLA Solomon Scholars Research Day May 30th 2023. Los Angeles, CA, United States.